Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Gains from Investment Securities (2016 - 2025)

Immucell (ICCC) has disclosed Gains from Investment Securities for 10 consecutive years, with -$2263.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gains from Investment Securities fell 111.06% year-over-year to -$2263.0, compared with a TTM value of -$5905.0 through Sep 2025, down 139.25%, and an annual FY2024 reading of $480500.0, changed N/A over the prior year.
  • Gains from Investment Securities was -$2263.0 for Q3 2025 at Immucell, up from -$35735.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $84000.0 in Q3 2021 and bottomed at -$51992.0 in Q2 2024.
  • Average Gains from Investment Securities over 5 years is $5171.3, with a median of $1960.0 recorded in 2021.
  • Peak annual rise in Gains from Investment Securities hit 29991.18% in 2024, while the deepest fall reached 12247.66% in 2024.
  • Year by year, Gains from Investment Securities stood at $1961.0 in 2021, then plummeted by 32.33% to $1327.0 in 2022, then soared by 588.7% to $9139.0 in 2023, then plummeted by 164.61% to -$5905.0 in 2024, then soared by 61.68% to -$2263.0 in 2025.
  • Business Quant data shows Gains from Investment Securities for ICCC at -$2263.0 in Q3 2025, -$35735.0 in Q2 2025, and $37998.0 in Q1 2025.